In addition, low TUBA1B expression has been associated with adverse effects on the overall survival (OS) of patients with colon adenocarcinoma (COAD), leading to CD8 + T cell depletion and impacting COAD patients' response to immunotherapy13. Here, TUBA1B is linked to colon adenocarcinoma.